Japanese Doctors Confirm Rare Heart Condition After COVID Shot

Written by John Michael-Dumais on July 25, 2024. Posted in Current News

A case study from Japan has documented the first known biopsy-proven instance of inflammatory dilated cardiomyopathy (iDCM) .

A condition where the heart becomes enlarged and weakened due to inflammation — following COVID-19 vaccination.

Doctors at Narita-Tomisato Tokushukai Hospital in Chiba, Japan, used an endomyocardial biopsy to diagnose iDCM in a 78-year-old woman who developed heart problems after receiving her third COVID-19 vaccine dose.

The patient had previously received two doses of the Pfizer-BioNTech BNT162b2 mRNA vaccine, followed by a Moderna mRNA-1273 booster.

The case, reported on July 1 in a peer-reviewed open-access article in the journal ESC Heart Failure, marks a significant advancement in understanding potential cardiac complications related to COVID-19 vaccines.

By using tissue analysis, doctors were able to more definitively link the heart condition to the vaccination, distinguishing it from other possible causes.

“While such severe reactions remain extremely rare, this case demonstrates the value of advanced diagnostic techniques in identifying and understanding vaccine-related side effects,” the doctors wrote.

The patient was successfully treated with a corticosteroid, which improved her condition significantly but not completely.

This outcome underscores the importance of prompt medical attention and accurate diagnosis for any unusual symptoms following vaccination. “Severe cases can be fatal if left untreated,” the doctors wrote.

Dr. Peter McCullough agreed, telling The Defender that his January paper with Jessica Rose, Ph.D., and Nicolas Hulscher showed that in thousands of vaccine-associated myocarditis cases, the mortality rate is 2.9%.

McCullough said the Japanese paper is important because it applies to heart failure occurring months to years after COVID-19 vaccination. For patients with similar symptoms, doctors should seriously consider the possibility that the COVID-19 vaccine might have caused the damage, he said.

Brian Hooker, Ph.D., chief scientific officer at Children’s Health Defense, told The Defender the case study was “very robust.”

“They rule out cardiac infection as well as chronic myocarditis via autoimmunity in order to deduce a diagnosis of vaccine-associated myocarditis,” Hooker said.

Patient was ‘in acute heart failure’

The patient, with no prior history of heart disease, experienced palpitations and shortness of breath on the fourth day after receiving her third COVID-19 vaccine dose. Her symptoms gradually worsened and she was admitted to the hospital 11 days post-vaccination.

“By the time she was admitted to our hospital, she was in acute heart failure,” the doctors explained.

Upon examination, they noted several concerning signs:

• Rapid heartbeat of 120 beats per minute.
• Swollen neck veins and leg edema.
• Abnormal heart sounds, including a gallop rhythm and heart murmur.
• Low blood oxygen levels.

Diagnostic tests indicated cardiac dysfunction. An electrocardiogram (EKG) showed an abnormally rapid heart rate with disrupted electrical conduction patterns in both the right and left sides of the heart.

Blood tests revealed elevated levels of cardiac troponin I and brain natriuretic peptide, both markers of myocardial stress and damage. An EKG demonstrated severely reduced left ventricular function, with an ejection fraction of only 20%.

To rule out coronary artery disease, the medical team performed an X-ray test called coronary angiography, which showed no significant obstructions.

The constellation of symptoms and test results led the physicians to diagnose iDCM, potentially associated with the recent COVID-19 vaccination. To establish a definitive diagnosis, they proceeded with an endomyocardial biopsy.

Responding to a tweet about the Japanese study, Lori Petersen, injured by the Pfizer vaccine, posted this on X (formerly Twitter) on Thursday:

Key findings

The endomyocardial biopsy provided crucial insights into the patient’s condition. Under the microscope, doctors observed signs of inflammation in the heart tissue, confirming the diagnosis of iDCM. These signs included:

• Enlarged heart muscle cells.
• Scarring between the cells.
• Clusters of inflammatory cells, primarily macrophages and T-lymphocytes, or T-cells.

The biopsy also revealed increased levels of tenascin-C, a protein that is typically elevated during active heart inflammation. This suggested the patient’s condition was in an active stage and potentially treatable.

A cardiac MRI, another advanced imaging technique, showed additional signs of heart damage. It revealed an enlarged left ventricle and a pattern of scarring in the heart muscle wall that’s often seen in non-infectious causes of heart inflammation.

“The biopsy allowed us to directly observe the inflammatory process in the heart tissue, providing a level of certainty we haven’t had in previous cases of suspected vaccine-related heart issues,” the doctors wrote.

They emphasized how this case differs from previously reported vaccine-related heart issues. “Most reported cases of heart inflammation after COVID-19 vaccination have been myocarditis in young males. This case of iDCM in an older female patient expands our understanding of potential cardiac complications.”

The detailed findings allowed doctors to distinguish this case from other types of heart

Follow-up examinations at six months showed ‘significant improvements’

After confirming the diagnosis of iDCM through biopsy, doctors initiated a targeted treatment plan involving the oral corticosteroid prednisolone to reduce inflammation in the heart.

The medical team also administered standard heart failure medications, including:

• Enalapril, to help relax blood vessels.
• Spironolactone, a diuretic that also has anti-inflammatory properties.
• Dapagliflozin, a newer medication shown to be beneficial in heart failure.

The patient’s condition improved steadily following treatment. After 16 days in the hospital, she was discharged with a reduced dose of prednisolone.

Follow-up examinations at six months showed significant improvements in the patient’s heart function. “The echocardiogram revealed a dramatic recovery in the heart’s pumping ability,” the doctors wrote. “The left ventricular ejection fraction improved from 20% to 56%, which is within the normal range.”

The follow-up cardiac MRI confirmed the reversal of the earlier abnormalities, showing a reduction in heart size and improved function. Additionally, a repeat biopsy demonstrated a marked decrease in inflammation within the heart tissue.

The patient remained stable without any recurrence of symptoms during the one-year follow-up period.

Hooker’s assessment of the patient’s recovery was more restrained. “This sounds more like chronic myocarditis (scarring and enlarged heart) rather than acute myocarditis where the chance of a full recovery is about 66% within 2-3 months.”

Hooker pointed out that scarring of the heart is permanent and in this case, the heart’s ejection fraction had not completely recovered by the six-month follow-up appointment.

Vigilance and investigation of potential vaccine-related adverse events needed

The case study provides new insights into the spectrum of cardiac complications potentially linked to COVID-19 vaccines. The researchers emphasized several key points in their discussion.

Current understanding of COVID-19 vaccine-associated myocarditis primarily involves cases in young males, often occurring after the second vaccine dose.

Hooker noted that the young males have the highest risk of heart damage from the mRNA vaccines.

These myocarditis cases typically show an abundance of lymphocytes, a type of white blood cell, infiltrating the heart tissue.. But this case diverges from the typical vaccine-associated myocarditis profile in several ways:

• The patient was an older female.
• The complication occurred after a third dose of a different COVID-19 vaccine.
• The diagnosis was specifically iDCM.

The biopsy findings revealed a mix of macrophages and T-lymphocytes in the heart tissue — immune system cells designed to rid the body of infection and disease — along with cardiac microthrombi (tiny blood clots).

This pattern differs from previously reported vaccine-associated myocarditis cases and other types of vaccine-related heart inflammation. This underscores the complexity of immune responses to vaccines, the doctors wrote.

The researchers stressed the importance of considering iDCM in patients who present with heart failure symptoms following COVID-19 vaccination, particularly when the clinical picture doesn’t match typical myocarditis.

“Clinicians should not hesitate to perform EMB [endomyocardial biopsy] on patients presenting with the DCM [dilated cardiomyopathy] phenotype following SARS-CoV-2 immunization,” the doctors emphasized.

McCullough said that he considers all vaccine recipients to have potentially suffered cardiac damage. “In my clinical practice … I take a tiered approach with history, exam, ECG, laboratories and in selected cases, echocardiography/cardiac MRI.”

The Japanese team acknowledged that while such severe reactions remain extremely rare, this case highlights the need for continued vigilance and thorough investigation of potential vaccine-related adverse events.

See more at The Defender

Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method

PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 

Trackback from your site.